Logo image of FGEN

FIBROGEN INC (FGEN) Stock Fundamental Analysis

NASDAQ:FGEN - US31572Q8087 - Common Stock

10.35 USD
-0.28 (-2.63%)
Last: 8/26/2025, 8:00:00 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to FGEN. FGEN was compared to 547 industry peers in the Biotechnology industry. FGEN may be in some trouble as it scores bad on both profitability and health. FGEN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year FGEN has reported negative net income.
In the past year FGEN has reported a negative cash flow from operations.
FGEN had negative earnings in each of the past 5 years.
In the past 5 years FGEN reported 4 times negative operating cash flow.
FGEN Yearly Net Income VS EBIT VS OCF VS FCFFGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

With an excellent Return On Assets value of -1.16%, FGEN belongs to the best of the industry, outperforming 88.85% of the companies in the same industry.
Industry RankSector Rank
ROA -1.16%
ROE N/A
ROIC N/A
ROA(3y)-45.81%
ROA(5y)-39.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FGEN Yearly ROA, ROE, ROICFGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

With an excellent Gross Margin value of 128.07%, FGEN belongs to the best of the industry, outperforming 99.27% of the companies in the same industry.
FGEN's Gross Margin has declined in the last couple of years.
FGEN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 128.07%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.51%
GM growth 5Y-13.76%
FGEN Yearly Profit, Operating, Gross MarginsFGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

1

2. Health

2.1 Basic Checks

FGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, FGEN has more shares outstanding
The number of shares outstanding for FGEN has been increased compared to 5 years ago.
FGEN has a worse debt/assets ratio than last year.
FGEN Yearly Shares OutstandingFGEN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
FGEN Yearly Total Debt VS Total AssetsFGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

FGEN has an Altman-Z score of -16.61. This is a bad value and indicates that FGEN is not financially healthy and even has some risk of bankruptcy.
FGEN has a Altman-Z score of -16.61. This is amonst the worse of the industry: FGEN underperforms 81.35% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -16.61
ROIC/WACCN/A
WACC14.75%
FGEN Yearly LT Debt VS Equity VS FCFFGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

FGEN has a Current Ratio of 1.04. This is a normal value and indicates that FGEN is financially healthy and should not expect problems in meeting its short term obligations.
FGEN has a worse Current ratio (1.04) than 86.11% of its industry peers.
A Quick Ratio of 1.02 indicates that FGEN should not have too much problems paying its short term obligations.
The Quick ratio of FGEN (1.02) is worse than 85.74% of its industry peers.
Industry RankSector Rank
Current Ratio 1.04
Quick Ratio 1.02
FGEN Yearly Current Assets VS Current LiabilitesFGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 99.04% over the past year.
The Revenue for FGEN has decreased by -69.18% in the past year. This is quite bad
FGEN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -35.07% yearly.
EPS 1Y (TTM)99.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53%
Revenue 1Y (TTM)-69.18%
Revenue growth 3Y-49.88%
Revenue growth 5Y-35.07%
Sales Q2Q%-97.34%

3.2 Future

FGEN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.11% yearly.
The Revenue is expected to grow by 9.58% on average over the next years. This is quite good.
EPS Next Y122.87%
EPS Next 2Y9.49%
EPS Next 3Y-10.94%
EPS Next 5Y15.11%
Revenue Next Year-92.86%
Revenue Next 2Y-81.1%
Revenue Next 3Y-67.07%
Revenue Next 5Y9.58%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
FGEN Yearly Revenue VS EstimatesFGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
FGEN Yearly EPS VS EstimatesFGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -20 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FGEN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FGEN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FGEN Price Earnings VS Forward Price EarningsFGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FGEN Per share dataFGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40

4.3 Compensation for Growth

FGEN's earnings are expected to decrease with -10.94% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.49%
EPS Next 3Y-10.94%

More info and screens

0

5. Dividend

5.1 Amount

FGEN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FIBROGEN INC

NASDAQ:FGEN (8/26/2025, 8:00:00 PM)

10.35

-0.28 (-2.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/amc
Earnings (Next)11-10 2025-11-10/amc
Inst Owners31.01%
Inst Owner Change-96.76%
Ins Owners1.42%
Ins Owner Change1.04%
Market Cap41.81M
Analysts80
Price Target43.86 (323.77%)
Short Float %3.52%
Short Ratio0.56
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)82.57%
Min EPS beat(2)20.04%
Max EPS beat(2)145.1%
EPS beat(4)4
Avg EPS beat(4)109.14%
Min EPS beat(4)20.04%
Max EPS beat(4)226.05%
EPS beat(8)7
Avg EPS beat(8)63%
EPS beat(12)8
Avg EPS beat(12)40.12%
EPS beat(16)11
Avg EPS beat(16)583.04%
Revenue beat(2)1
Avg Revenue beat(2)14.05%
Min Revenue beat(2)-49.76%
Max Revenue beat(2)77.86%
Revenue beat(4)3
Avg Revenue beat(4)39.29%
Min Revenue beat(4)-49.76%
Max Revenue beat(4)98.39%
Revenue beat(8)6
Avg Revenue beat(8)28.13%
Revenue beat(12)9
Avg Revenue beat(12)20.88%
Revenue beat(16)11
Avg Revenue beat(16)17.71%
PT rev (1m)-82.8%
PT rev (3m)330%
EPS NQ rev (1m)-7.69%
EPS NQ rev (3m)-2777.78%
EPS NY rev (1m)122.19%
EPS NY rev (3m)627.45%
Revenue NQ rev (1m)9.23%
Revenue NQ rev (3m)-92.06%
Revenue NY rev (1m)27.19%
Revenue NY rev (3m)-86.86%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.78
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.38
EYN/A
EPS(NY)-9.61
Fwd EYN/A
FCF(TTM)-5.86
FCFYN/A
OCF(TTM)-5.8
OCFYN/A
SpS13.26
BVpS-55.2
TBVpS-55.2
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.16%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 128.07%
FCFM N/A
ROA(3y)-45.81%
ROA(5y)-39.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.51%
GM growth 5Y-13.76%
F-Score3
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.38%
Cap/Sales 0.47%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.04
Quick Ratio 1.02
Altman-Z -16.61
F-Score3
WACC14.75%
ROIC/WACCN/A
Cap/Depr(3y)133.57%
Cap/Depr(5y)124.53%
Cap/Sales(3y)11.27%
Cap/Sales(5y)9.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53%
EPS Next Y122.87%
EPS Next 2Y9.49%
EPS Next 3Y-10.94%
EPS Next 5Y15.11%
Revenue 1Y (TTM)-69.18%
Revenue growth 3Y-49.88%
Revenue growth 5Y-35.07%
Sales Q2Q%-97.34%
Revenue Next Year-92.86%
Revenue Next 2Y-81.1%
Revenue Next 3Y-67.07%
Revenue Next 5Y9.58%
EBIT growth 1Y21.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-12.3%
EBIT Next 3Y-5.41%
EBIT Next 5Y0.07%
FCF growth 1Y92.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y92.59%
OCF growth 3YN/A
OCF growth 5YN/A